HRMY — Harmony Biosciences Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $1.54bn
- $923.41m
- $868.45m
Annual cashflow statement for Harmony Biosciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 34.6 | 181 | 129 | 145 | 159 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 44.5 | 29.7 | 44.6 | 86.8 | 79.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.631 | -4.11 | 35 | -7.32 | 91.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 98.6 | 144 | 219 | 220 | 348 |
| Capital Expenditures | -100 | -40.2 | -0.312 | -1.15 | -19.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -102 | -46.1 | -66.3 | -20.1 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -100 | -142 | -46.4 | -67.5 | -39.6 |
| Financing Cash Flow Items | -31.5 | 0 | -9.36 | -2.5 | -3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.42 | 6.84 | -106 | -11 | -9.05 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.68 | 9.47 | 67.4 | 141 | 300 |